Financing ·
ProQR Therapeutics N.V. entered into an underwriting agreement on June 25, 2026, for a registered direct offering of…
PRQRProQR Therapeutics N.V.
ProQR Therapeutics N.V. entered into an underwriting agreement on June 25, 2026, for a registered direct offering of 27,624,310 ordinary shares at $1.81 per share, expected to net approximately $46.5 million. Concurrently, the company entered into a share purchase agreement with Eli Lilly and Company for a private placement of 5,100,780 shares at the same price, generating approximately $9.2 million. ProQR Therapeutics N.V. is a biotechnology company focused on RNA-based therapeutics.